Search Results
INVESTING IN THE BEST: OUR 2015 OPERATING GRANT WINNERS
We only invest in the best research. But how do we choose? How do we predict which research project is the most promising hope for the future? The answer is peer review—a tried...
READ MORENEW RESEARCH BEGINNINGS: MAKING IDEAS INTO REALITY
July is a month of new beginnings. At Fighting Blindness Canada, July 1st marks the start of a new research year. While our nation was celebrating Canada Day, we were also celebrating the...
READ MORECAN VALPROIC ACID (VPA) BE USED TO TREAT RETINITIS PIGMENTOSA? THE ANSWER IS IN THE GENE
Although winning a research award can help motivate scientists, Ruanne Lai doesn’t need extra motivation. For Ruanne, science is a “way of life” rather than simply a job. Ruanne’s recent win, however,...
READ MOREVALPROIC ACID AS A TREATMENT FOR RETINITIS PIGMENTOSA
Clinical trials of valproic acid for the treatment of retinitis pigmentosa began in both the USA and Korea in late 2011. As well, a smaller shorter open-label trial was begun in Japan....
READ MOREEYELEA APPROVED TO TREAT WET AMD IN CANADA
An additional treatment option for people with wet age-related macular degeneration (AMD) will soon be available in Canada. Health Canada has just approved Eyelea, a drug made and marketed by Bayer Inc....
READ MOREVALPROIC ACID: THE PERILS OF USING DRUGS OFF-LABEL
Almost three years ago, scientists at the University of Massachusetts Medical School reported on a preliminary clinical trial of the epilepsy drug, valproic acid, as potential treatment for autosomal dominant retinitis pigmentosa...
READ MOREJoin the Fight!
Learn how your support is helping to bring a future without blindness into focus! Be the first to learn about the latest breakthroughs in vision research and events in your community by subscribing to our e-newsletter that lands in inboxes the beginning of each month.